Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Myeloid, Acute
Conditions
Leukemia, Myeloid, Acute, AML Stage, Adult
Trial Timeline
Dec 1, 2022 → Dec 31, 2026
NCT ID
NCT05603884About Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen is a phase 2 stage product being developed by CSPC Pharmaceutical Group Limited for Leukemia, Myeloid, Acute. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05603884. Target conditions include Leukemia, Myeloid, Acute, AML Stage, Adult.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Myeloid, Acute were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05603884 | Phase 2 | Recruiting |
Competing Products
20 competing products in Leukemia, Myeloid, Acute